共查询到20条相似文献,搜索用时 46 毫秒
1.
目的:通过建立慢病毒载体感染猪胚胎体系实现胚胎标记,进而研究不同发育阶段猪孤雌胚胎之间的嵌合能力,为进一步研究猪早期胚胎发育以及细胞分化奠定基础.方法:首先,通过显微注射的方法把2×109I.U./ml、2×108I.U./ml和2×107I.U./ml三个梯度的表达绿色荧光的慢病毒载体分别注射到猪1-细胞胚胎和2-细胞胚胎的透明带下,进行胚胎的GFP转基因标记,在荧光显微镜下观察比较卵裂率、阳性胚胎率、囊胚率、阳性囊胚率和囊胚细胞数.然后,采用凹窝聚合法对同步发育胚胎在不同阶段(2-细胞,4-细胞,8-细胞)进行嵌合,2-细胞胚胎与不同发育阶段(2-细胞、4-细胞、8-细胞)胚胎进行嵌合以及2-细胞胚胎卵裂球互换制作嵌合体胚胎,发育到囊胚时在荧光显微镜下检测胚胎的嵌合状态.结果:2×109I.U./ml的慢病毒感染猪2-细胞胚胎组中,体外受精和孤雌胚胎感染阳性率( 80.00%、76.36%)和阳性囊胚率(90.74%、89.56%)都显著高于其它滴度组(P<0.05),另外,慢病毒感染的两种胚胎与对照组对卵裂率、囊胚率和囊胚细胞数三个指标没有显著影响(P>0.05).2-细胞胚胎之间嵌合囊胚率和2-细胞卵裂球互换嵌合囊胚率( 53.85%、62.50%)显著高于2-细胞胚胎与4-细胞胚胎的嵌合率(18.60%,P<0.05),在同步发育胚胎中8-细胞胚胎之间的嵌合率(75.00%)高于4-细胞胚胎之间和2-细胞胚胎之间的嵌合率( 65.00%、53.80%).结论:2×109I.U./ml的慢病毒感染2-细胞期胚胎效率最高,另外,慢病毒感染对猪胚胎发育没有明显影响.8-细胞间的嵌合率比较高;发育同步胚胎间的嵌合率高于发育非同步胚胎间的嵌合率. 相似文献
2.
从早期胚胎多能干细胞生成的嵌合鼠 总被引:9,自引:2,他引:7
本文利用囊胚注射法将小鼠胚胎多能干细胞-CCE细胞注射到发育3天半的昆明和C37BL/6J小鼠受体囊胚腔内,经假孕鼠借腹怀胎,获3只CCE细胞毛色嵌合鼠。实验共注射胚胎654个,经培养其恢复成活率73.8%,胚胎移植后,假母受孕率及产仔率分别为32.9%和53%。在所获3只嵌合鼠中,2只为CCE-昆明毛色嵌合鼠,1只为CCE-C37BL/6J毛色嵌合鼠,这是国内首次利用胚胎多能干细胞获得嵌合鼠。为 相似文献
3.
远交系小鼠胚胎干细胞系的建立及嵌合鼠的获得 总被引:2,自引:0,他引:2
ES细胞(Embryonic Stcm Cells)是来源小鼠早期胚胎的多潜能干细胞,它可以在体外大量培养,并以单细胞的形式注射到早期胚胎里,发育为嵌合体,到目前为止,通常使用的129小鼠品系是来源于近交系(inbrcd)小鼠的胚胎。与之相比,远交系小鼠应当具有较强的生命力和抗病能力。曾有人报道过建成了远交系小鼠胚胎干细胞系,但是尚没有见到获得嵌合鼠的报道。有人甚至认为:由于不同品系小鼠所具有的遗传背景不同,有的小鼠不能建成ES细胞系。最近,本实验室在这方面做了有益的探索,成功地建成了远交系小鼠胚胎干细胞系,并在这里报导首例用远交小鼠胚胎干细胞系培育成功嵌合体小鼠。采用源于Swiss小鼠远交群的昆明(KM)品系小鼠囊胚建成了三个小鼠胚胎干细胞系(KE1,KE2,KE5)。核型正常率均达到70%以上。自第八代起分批存。复苏后,培养至第12代,消化成单细胞,通过囊胚显微注射,将其注射到615品系小鼠胚胎。在幸存的幼鼠中获得了一只来源于KE1细胞的嵌合鼠(Table1)。其毛色表现为受体鼠(615)的白色中嵌合有供体鼠(KM)黑褐色(Platc I-A)。嵌合鼠与受体鼠的杂交后代鼠中仍然出现了受体鼠的毛色类型(PlateI-B)。证明:ES细胞能嵌合到生殖腺并形成具有正常功能的配子,从而产生种系嵌合鼠。 相似文献
4.
食蟹猴-猪异种体细胞核移植(Interspecies somatic cell nuclear transfer,iSCNT)研究旨在由iSCNT胚胎建立具有与人类相似遗传背景的胚胎干细胞(ESCs),作为医学和基础科学研究的实验材料。文章探讨了两种组蛋白脱乙酰化酶抑制剂(HDACi)Trichostatin A(TSA)和Valproic acid(VPA)处理浓度、时间与培养液(PZM-3和HECM-10)组合对食蟹猴-猪iSCNT胚胎早期发育的影响。结果表明,在PZM-3中添加10 nmol/L TSA处理48 h组的囊胚率显著高于对照组(22.78%vs 9.86%,P<0.05)。但是,不管在PZM-3或是HECM-10中,添加2~10mmol/L VPA处理均不能提高iSCNT胚胎早期发育能力。文章证明了TSA处理可以提高食蟹猴-猪iSCNT胚胎早期发育能力。 相似文献
5.
本研究观察了大小鼠异种间嵌合胚在体外 培养条件下以及移植后的发育情况。采用聚合法使Wistar-Imamichi大鼠和ICR小鼠的早期胚胎聚合为一体,然后用于体外培养,并进行移植。实验结果表明,大小鼠异种间嵌合胚在含20%FCS的Whitten溶液中有80.8%的胚可发育为囊胚期胚胎。这种胚胎在受体大鼠和小鼠,均能着床,着床率分别为51.3%和53.7%,没有显著差异。着床后的胚胎能够维持到妊娠第10天左右,但以后很快退化、死亡,其原因有待进一步探索。 相似文献
6.
通过显微注射法构建ES细胞(MESPU 13)嵌合小鼠 总被引:4,自引:1,他引:3
为了研究一个新建的小鼠胚胎干细胞系(ES细胞系)MESPU 13,我们将ES细胞显微注射到C57BL/6J小鼠的囊胚中构建嵌合鼠。在注射了2-9个ES细胞的136个囊胚中,127个囊胚(93%)经过3个小时的培养后重新出现囊胚腔。当把119个恢复的囊胚移植到假孕雌鼠的子宫内时,获得63只(52.9%)出生鼠。在59只存活到可以判断毛色阶段的小鼠中,有21只(35.6%)被判定为嵌合鼠。显示了该ES细胞系具有较高的嵌合能力。 相似文献
7.
《中国实验动物学报》2015,(4)
目的考察不同品系的小鼠囊胚对C57BL/6胚胎干细胞种系嵌合效率的影响,进而提高通过在C57BL/6胚胎干细胞中同源重组制作基因打靶小鼠的效率。方法选取近交系B6(Cg)-Tyrc-2J和BALB/c品系及封闭群ICR作为囊胚供体鼠,通过在TLX3、Ai3K和SL三个不同基因修饰ES细胞的种系嵌合实验中,平行比较三者的囊胚利用率、嵌合鼠获得效率以及种系遗传效率等三个方面,并进一步针对囊胚来源这一因素对效率的影响进行统计学分析。结果三种ES细胞均未能通过B6(Cg)-Tyrc-2J品系囊胚的注射获得种系遗传。而BALB/c品系与ICR品系相比,囊胚利用率明显低于ICR品系(P0.05);嵌合鼠获得效率方面,BALB/c与ICR相当(P=0.115);而种系遗传效率方面,BALB/c品系显著高于其他品系(P0.01)。结论 BALB/c品系在C57BL/6胚胎干细胞种系嵌合效率方面确实具有优势,然而,由于BALB/c囊胚较难获得,并且存在发育延迟和透明带脆性高等问题,而ICR品系在囊胚获得和利用方面的效率明显高于BABL/c,并且也可以支持C57BL/6胚胎干细胞的种系遗传,因此也是C57BL/6胚胎干细胞囊胚注射中较好的选择。 相似文献
8.
《中国科学:生命科学》2016,(7)
多能干细胞(PSCs)具有发育的多潜能性,可以分化为机体各种细胞类型,是再生医学领域进行细胞替代治疗以及组织/器官再生的基础.如何由终末分化的体细胞重编程获得病人特异的PSCs,是再生医学领域的核心问题之一,目前主要采取两种重编程策略:借助核移植技术由早期胚胎体外建系获得,或通过诱导重编程技术获得.本文将综述不同多能性等级PSCs的获得方法以及其在多能性机制研究中的应用,并讨论PSCs通过异种嵌合实现组织/器官再造的潜在应用价值.PSCs的研究不仅推动了基础生物学研究的发展,同时也为再生医学走向临床开辟了道路. 相似文献
9.
ES细胞嵌合能力的强弱是人们利用ES细胞获得转基因小鼠时十分关心的问题。本言语通过囊胚显微注射法将15个左右ES细胞注入C57BL/6J品系小鼠3.5天囊胚的囊胚腔中观察嵌合鼠毛色嵌合情况。统计嵌合鼠的出生率;以及用葡萄糖磷酸异构酶(GPI)电泳地检测ES细胞在嵌合鼠体内各种组织和器官的嵌合情况,对于HPRT缺陷(HDC)细胞和MESPU-13细胞的嵌合能力我们作了较详细的研究,结果表明MESPU 相似文献
10.
组蛋白异常修饰是克隆胚胎发育的重要制约因素,组蛋白H3K9me3去甲基化酶KDM4家族的过表达可以有效提高克隆胚胎的发育效率。为探究过表达H3K9me3去甲基化酶对猪克隆胚胎发育的影响,本研究在猪克隆胚胎1-细胞期和2-细胞期分别注射KDM4A mRNA和KDM4D mRNA检测胚胎的囊胚率;收集1-细胞期注射KDM4A mRNA和胚胎注射水(对照组)的2-细胞期克隆胚胎检测H3K9me3表达水平;此外,收集1-细胞期注射KDM4A mRNA和胚胎注射水的4-细胞期克隆胚胎进行单细胞转录组测序,并对测序数据进行GO与KEGG富集分析。结果显示:在1-细胞期注射KDM4A mRNA的猪克隆胚胎囊胚率显著高于对照组(25.32±0.74%vs14.78±0.87%),注射KDM4D mRNA对猪克隆胚胎囊胚率无明显作用(16.27±0.77%vs 14.78±0.87%);在2-细胞期注射KDM4A mRNA和KDM4D mRNA的克隆胚胎囊胚率与对照组相比均无显著差异(32.18±1.67%、30.04±0.91%vs 31.22±1.40%)。在1-细胞期注射KDM4A mRNA的克隆... 相似文献
11.
Pseudomonas exotoxin: chimeric toxins 总被引:17,自引:0,他引:17
Pseudomonas exotoxin binds to and enters cells by receptor-mediated endocytosis. Within the cell it requires exposure to low pH to enable it to translocate to the cell cytoplasm where it inhibits protein synthesis by ADP-ribosylating elongation factor 2. The toxin has three main structural domains whose functions are: Ia, cell binding; II, translocation; and III, ADP-ribosylation. Key amino acids have been identified within each domain that are required for the function of the toxin. Chimeric toxins were made originally by using chemical cross-linking reagents to couple Pseudomonas exotoxin (or other toxins) to cell-binding proteins. More recently, a variety of Pseudomonas exotoxin-related chimeric toxins have been made by gene fusion technology. These chimeric toxins may be useful clinically for treating various diseases and experimentally for understanding receptor function. 相似文献
12.
13.
14.
Generation of chimeric rhesus monkeys 总被引:1,自引:0,他引:1
Totipotent cells in early embryos are progenitors of all stem cells and are capable of developing into a whole organism, including extraembryonic tissues such as placenta. Pluripotent cells in the inner cell mass (ICM) are the descendants of totipotent cells and can differentiate into any cell type of a body except extraembryonic tissues. The ability to contribute to chimeric animals upon reintroduction into host embryos is the key feature of murine totipotent and pluripotent cells. Here, we demonstrate that rhesus monkey embryonic stem cells (ESCs) and isolated ICMs fail to incorporate into host embryos and develop into chimeras. However, chimeric offspring were produced following aggregation of totipotent cells of the four-cell embryos. These results provide insights into the species-specific nature of primate embryos and suggest that a chimera assay using pluripotent cells may not be feasible. 相似文献
15.
16.
Xiong H Ran Y Xing J Yang X Li Y Chen Z 《Journal of biochemistry and molecular biology》2005,38(4):414-419
The production of recombinant antibodies has been generally recognized as time-consuming and labor-intensive. The aim of our study is to construct mammalian expression vectors containing the cDNA encoding the human constant regions and murine variable regions to massively and cost-effectively produce full-length chimeric antibodies. Unique restriction sites flanking the Ig variable region were designed to allow for the replacement of variable regions generated by PCR. Western blot analysis of the chimeric antibodies revealed that the expressed products were of the predicted size, structure and specificity. The usefulness of the vectors was confirmed by construction of human-mouse chimeric antibody-HCAb which secretes murine antibody against the human colorectal cancer. Selected in medium containing gradually increasing methotrexate (MTX), clones with increased expression of the product gene can be efficiently generated. The secretion of recombinant chimeric antibody-HCAb yielded 30 pg cell(-1) day(-1) at 10(-6 )M MTX. With this high-level expression from pools, the convenient and rapid production of over 100 milligram amounts per liter of recombinant antibodies may be achieved, which indicates the significant roles of pYR-GCEVH and pYR-GCEVL in the production of chimeric antibodies. 相似文献
17.
Processivity of chimeric class V myosins 总被引:1,自引:0,他引:1
Unconventional myosin V takes many 36-nm steps along an actin filament before it dissociates, thus ensuring its ability to move cargo intracellularly over long distances. In the present study we assessed the structural features that affect processive run length by analyzing the properties of chimeras of mouse myosin V and a non-processive class V myosin from yeast (Myo4p) (Reck-Peterson, S. L., Tyska, M. J., Novick, P. J., and Mooseker, M. S. (2001) J. Cell Biol. 153, 1121-1126). Surprisingly a chimera containing the yeast motor domain on the neck and rod of mouse myosin V (Y-MD) showed longer run lengths than mouse wild type at low salt. Run lengths of mouse myosin V showed little salt dependence, whereas those of Y-MD decreased steeply with ionic strength, similar to a chimera containing yeast loop 2 in the mouse myosin V backbone. Loop 2 binds to acidic patches on actin in the weak binding states of the cycle (Volkmann, N., Liu, H., Hazelwood, L., Krementsova, E. B., Lowey, S., Trybus, K. M., and Hanein, D. (2005) Mol. Cell 19, 595-605). Constructs containing yeast loop 2, which has no net charge compared with +6 for wild type, showed a higher K(m) for actin in steady-state ATPase assays. The results imply that a positively charged loop 2 and a high affinity for actin are important to maintain processivity near physiologic ionic strength. 相似文献
18.
Karoli T Mamidyala SK Zuegg J Fry SR Tee EH Bradford TA Madala PK Huang JX Ramu S Butler MS Cooper MA 《Bioorganic & medicinal chemistry letters》2012,22(7):2428-2433
The rise of antibiotic resistance is of great clinical concern. One approach to reducing the development of resistance is to co-administer two or more antibiotics with different modes of action. However, it can be difficult to control the distribution and pharmacokinetics of two drugs to ensure both concentrations remain within the range of therapeutic efficacy whilst avoiding adverse effects. Hybrid drugs, where two drugs are linked together with a flexible linker, have been explored, but the resultant large, flexible molecules can have poor bioavailability. We have developed a chimeric approach using click chemistry where the pharmacophores of two drugs are overlapped into a single smaller, more drug-like molecule. Design and selection of compounds were assisted by in silico structural docking. We prepared a series of compounds that include candidates showing activity against the targets of both trimethoprim; dihydrofolate reductase, and ciprofloxacin; DNA gyrase and topoisomerase IV. The resultant triazole containing molecules show modest, but broad spectrum activities against drug sensitive and resistant Gram-negative and Gram-positive bacteria, with no observable cytotoxicity. 相似文献
19.
20.
K A Feldmann 《Nature biotechnology》1999,17(9):857-858